← Home / Decoy Therapeutics Inc. (DCOY)
Stock Analysis
Decoy Therapeutics Inc. (DCOY)
DCOY
DCOY · Market data
4.25 -2.52%
Track DCOY in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when DCOY price is:
52W Range Position
1%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-06 18:59 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
5.60
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
29
↗
Equity Offering / Capital Raise
HIGH
DCOY equity financing update
Securities Purchase Agreement On June 26, 2026, Decoy Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an institutional and accredited investor (the “Purchaser”) for a private placement of the Company’s securities (the...
8-K Filing • SEC EDGAR
What's Driving DCOY?
📈 Technical recovery is improving
Momentum is Neutral. Watch 5.60 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
39.5
Price Chart
DCOY — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Classic valuation · Ratios use trailing twelve months
Updated 2026-08-05
Loss
Earnings not meaningful
Earnings are negative or not useful, so sales, book value and cash-flow metrics matter more.
Market Cap
$2.3M
Company size
P/E
-0.2
Not meaningful
P/S
0.6
Low sales multiple
P/B
0.6
Low book multiple
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Manageable
💵 Revenue
0.00
≈ Insufficient
📈 Net Income
-2.22M
↘ Negative
🧮 EPS (Basic)
-4.18
↘ Negative
Decoy Therapeutics Inc.
Related Opportunities